Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Blood Pressure Imbalances and Circulatory Shock01:24

Blood Pressure Imbalances and Circulatory Shock

Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence and prognostic value of electrocardiographic changes in patients with myocardial injury after elective PCI.

Cardiovascular revascularization medicine : including molecular interventions·2026
Same author

Advancing Quality in the Evaluation, Surveillance, and Management of Aortic Stenosis: A Report From the AHA Target: AS Registry.

Circulation·2026
Same author

UNICORN During Transcatheter Aortic Valve Replacement in Native and Bioprosthetic Aortic Valves: A Multicenter Study.

JACC. Cardiovascular interventions·2026
Same author

Balloon-Assisted Translocation of the Mitral Anterior Leaflet to Prevent Outflow Tract Obstruction During TMVR: The BATMAN Registry.

JACC. Cardiovascular interventions·2026
Same author

Leaflet Modification to Mitigate Coronary Obstruction Risk During TAVR: Results From the LOFTER-TAVR Registry.

JACC. Cardiovascular interventions·2026
Same author

Transcatheter Tricuspid Valve Replacement for Severe Tricuspid Regurgitation Post-Left Ventricular Assist Device.

JACC. Case reports·2026

Related Experiment Video

Updated: May 31, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Mechanical Cardiocirculatory Support Devices in Valvular Cardiogenic Shock.

Chantal Y Asselin1, Mostafa Naguib1, James Slater2

  • 1Gagnon Cardiovascular Institute, Atlantic Health System, Morristown, NJ, USA.

Interventional Cardiology Clinics
|May 28, 2026
PubMed
Summary

Valvular heart dysfunction-related cardiogenic shock (VCS) is a complex condition with high mortality. This study offers a practical guide for selecting mechanical circulatory support (MCS) devices to improve outcomes.

Keywords:
Mechanical circulatory support devicesStructural heart diseaseValvular cardiogenic shock

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Related Experiment Videos

Last Updated: May 31, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Area of Science:

  • Cardiology
  • Cardiovascular Surgery
  • Critical Care Medicine

Background:

  • Valvular heart dysfunction-related cardiogenic shock (VCS) presents significant clinical challenges and high in-hospital mortality rates.
  • Timely intervention is critical for patient survival in VCS.
  • Mechanical circulatory support (MCS) devices offer a potential strategy to mitigate disease progression and improve survival in VCS.

Purpose of the Study:

  • To provide a practical approach to selecting the optimal mechanical circulatory support (MCS) device for patients with valvular heart dysfunction-related cardiogenic shock (VCS).
  • To synthesize current literature and clinical expertise to guide MCS device selection in VCS.

Main Methods:

  • Extensive review of existing medical literature on VCS and MCS.
  • Incorporation of clinical expertise from specialists in the field.
  • Development of a practical framework for MCS device selection.

Main Results:

  • Evidence supporting the use of MCS in VCS is growing.
  • Optimal selection of MCS devices for VCS remains a complex clinical decision.
  • A practical approach to MCS device selection can aid clinicians.

Conclusions:

  • Mechanical circulatory support (MCS) devices can be crucial in managing valvular heart dysfunction-related cardiogenic shock (VCS).
  • A structured approach to MCS device selection is necessary for effective VCS treatment.
  • Further research and clinical experience will continue to refine MCS strategies for VCS.